Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level

Antiviral Therapy

Volumn 8, Issue 6, 2003, Pages 617-626

  Nolan, David ^a   Hammond, Emma ^a   James, Ian ^a   McKinnon, Elizabeth ^a   Malla, Simon ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONFOCAL MICROSCOPY; DNA CONTENT; DRUG CHOICE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MITOCHONDRIAL DNA DEPLETION; PRIORITY JOURNAL;

ADIPOCYTES; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; BIOPSY; DNA, MITOCHONDRIAL; HUMANS; LIPODYSTROPHY; LONGITUDINAL STUDIES; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0346333250     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
2. John M, Nolan D & Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antiviral Therapy 2001; 6:9-20.
3. Bernasconi E, Boubaker K, Junghans C, Flepp M, Furrer HJ, Haensel A, Hirschel B, Boggian K, Chave JP, Opravil M, Weber R, Rickenbach M & Telenti A; Swiss HIV Cohort Study. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs: the Swiss HIV Cohort Study. Journal of Acquired Immune Deficiency Syndromes 2002; 31:50-55.
4. Mallal SA, John M, Moore CB, James IR & McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000; 14:1309-1316.
5. Saint-Marc T, Partisani M, Poizot-Martin I, Rouviere O, Bruno F, Avellaneda R, Lang JM, Gastaut JA & Touraine JL. Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing anti-retroviral therapy: preliminary results of the LIPOCO study. AIDS 2000; 14:37-49.
6. Joly V, Flandre P, Meiffredy V, Leturque N, Harel M, Aboulker JP & Yeni P. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16:2447-2454.
7. Law M, Emery S, French M, Carr A, Chuah J & Cooper D. Lipodystrophy and metabolic abnormalities in a cross-sectional study of participants in randomized controlled studies of combination antiretroviral therapy. 2nd International Workshop on Adverse Drug Reactions & Lipodystrophy. September 13-15 2000. Toronto, Canada. Abstract 028.
8. Chene G, Angelini E, Cotte L, Lang JM, Morlat P, Rancinan C, May T, Journot V, Raffi F, Jarrousse B, Grappin M, Lepeu G & Molina JM. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clinical Infectious Diseases 2002; 34:649-657.
9. Dube MP, Zackin R, Tebas P et al. Prospective study of regional body composition in antiretroviral-naive subjects randomized to receive zidovudine+lamivudine or didanosine+stavudine combined with nelfinavir, efavirenz, or both: A5005s, a substudy of ACTG 384. 4th International Workshop on Adverse Drug Reactions & Lipodystrophy. September 22-25 2002, San Diego, Calif., USA. Abstract 27.
10. Saint-Marc T, Partisani M, Poizot-Martin I, Bruno F, Rouviere O, Lang JM, Gastaut JA & Touraine JL. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999; 13:1659-1667.
11. Brinkman K, Smeitink JA, Romijn JA & Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-1115.
12. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS & Johnson KA. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. Journal of Biological Chemistry 2001; 276:40847-40857.
13. Martin JL, Brown CE, Matthews-Davis N & Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrobial Agents & Chemotherapy 1994; 38:2743-2749.
14. Hammond EL, Sayer D, Nolan D, Walker UA, Ronde A, Montaner JS, Cote HC, Gahan ME, Cherry CL, Wesselingh SL, Reiss P & Mallal S. Assessment of precision and concordance of quantitative mitochondrial DNA assays: a collaborative international quality assurance study. Journal of Clinical Virology 2003; 27:97-110.
15. Kingsley L, Smit E, Riddler S et al. Prevalence of lipodystrophy and metabolic abnormalities in the multicentre AIDS cohort study (MACS). 8th Conference on Retroviruses & Opportunistic Infections. February 4-8 2001. Chicago, Ill., USA. Abstract 538.
16. Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M & Cooper DA; Mitochondrial Toxicity (MITOX) Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. Journal of the American Medical Association 2002; 288:207-215.
17. Dreschler H & Powderly WG. Switching effective anti-retroviral therapy: a review. Clinical Infectious Diseases 2002; 35:1219-1230.
18. Cherry C, Nolan D, James I et al. Longitudinal associations between antiretroviral treatments and quantification of tissue mitochondrial DNA from ambulatory subjects with HIV infection. 10th Conference on Retroviruses & Opportunistic Infections. February 10-14 2003, Boston, Mass., USA. Abstract 133.
19. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B & Mallal S. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
20. Lloreta J, Domingo P, Pujol RM, Arroyo JA, Baixeras N, Matias-Guiu X, Gilaberte M, Sambeat MA & Serrano S. Ultrastructural features of highly active antiretroviral therapy-associated partial lipodystrophy. Virchows Archives 2002; 441:599-604.
21. Walker UA, Bickel M, Lutke Volksbeck SI, Ketelsen UP, Schofer H, Setzer B, Venhoff N, Rickerts V & Staszewski S. Evidence of nucleoside analogue reverse transcriptase inhibitor-associated genetic and structural defects of mitochondria in adipose tissue of HIV-infected patients. Journal of Acquired Immune Deficiency Syndromes 2002; 29:117-121.
22. Thompson K, McComsey G, Paulsen D et al. Improvements in body fat and mitochondrial DNA levels are accompanied by decreased adipose tissue apoptosis ler abacavir after replacement of stavudine therapy with either abacavir or stavudine. 10th Conference on Retroviruses & Opportunistic Infections. February 10-14 2003, Boston, Mass., USA. Abstract 728.
23. Domingo P, Matias-Guiu X, Pujol RM, Domingo JC, Arroyo JA, Sambeat MA & Vazquez G. Switching to nevirapine decreases insulin levels but does not improve subcutaneous adipocyte apoptosis in patients with highly active antiretroviral therapy-associated lipodystrophy. Journal of Infectious Diseases 2001; 184:1197-1201.
24. Behrens GM, Boerner AR, Weber K, van den Hoff J, Ockenga J, Brabant G & Schmidt RE. Impaired glucose phosphorylation and transport in skeletal muscle cause insulin resistance in HIV-1-infected patients with lipodystrophy. Journal of Clinical Investigation 2002; 110:1319-1327.
25. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P & Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
26. Noor MA, Seneviratne T, Aweeka FT, Lo JC, Schwarz JM, Mulligan K, Schambelan M & Grunfeld C. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002; 16:F1-F8.
27. Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, Cooper DA & Chisholm DJ. Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy. Diabetes 2002; 51:3163-3169.
28. Sekhar RV, Jahoor F, White AC, Pownall HJ, Visnegarwala F, Rodriguez-Barradas MC, Sharma M, Reeds PJ & Balasubramanyam A. Metabolic basis of HIV-lipodystrophy syndrome. American Journal of Physiology, Endocrinology & Metabolism 2002; 283:E332-E337.
29. Woerle HJ, Mariuz PR, Meyer C, Reichman RC, Popa EM, Dostou JM, Welle SL & Gerich JE. Mechanisms for the deterioration in glucose tolerance associated with HIV protease inhibitor regimens. Diabetes 2003; 52:918-925.
30. Ford ES, Giles WH & Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. Journal of the American Medical Association 2002; 287:356-359.